Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcγ receptor and complement-dependent effector mechanisms

Journal of Virology

Volumn 85, Issue 22, 2011, Pages 11567-11580

  Vogt, Matthew R ^a   Dowd, Kimberly A ^b   Engle, Michael ^a   Tesh, Robert B ^c   Johnson, Syd ^d   Pierson, Theodore C ^b   Diamond, Michael S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

^d Analytical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD16 ANTIGEN; CD45 ANTIGEN; COMPLEMENT COMPONENT C1Q; EPITOPE; FC RECEPTOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E24; MONOCLONAL ANTIBODY E28; MONOCLONAL ANTIBODY E34; MONOCLONAL ANTIBODY E53; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BRAIN; CELL POPULATION; CONTROLLED STUDY; CROSS REACTION; IMMUNOCOMPETENT CELL; MONOCYTE; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SURVIVAL TIME; T LYMPHOCYTE; VIRUS INFECTION; VIRUS LOAD; VIRUS NEUTRALIZATION; WEST NILE FLAVIVIRUS; WEST NILE FLAVIVIRUS INFECTION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; COMPLEMENT SYSTEM PROTEINS; CROSS REACTIONS; DISEASE MODELS, ANIMAL; IMMUNIZATION, PASSIVE; MICE; MICE, INBRED C57BL; PHAGOCYTOSIS; RECEPTORS, IGG; RODENT DISEASES; SURVIVAL ANALYSIS; VIRAL ENVELOPE PROTEINS; WEST NILE VIRUS;

FLAVIVIRUS; MUS; WEST NILE VIRUS;

EID: 80655146256     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05859-11     Document Type: Article

References (84)

1. Beasley, D. W. 2011. Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus. Immunotherapy 3:269-285.
2. Beasley, D. W., and A. D. Barrett. 2002. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J. Virol. 76:13097-13100.
3. Bedzyk, W. D., L. S. Johnson, G. S. Riordan, and E. W. Voss, Jr. 1989. Comparison of variable region primary structures within an anti-fluorescein idiotype family. J. Biol. Chem. 264:1565-1569.
4. Benhnia, M. R., et al. 2009. Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J. Virol. 83:1201-1215.
5. Ben-Nathan, D., I. Huitinga, S. Lustig, N. van Rooijen, and D. Kobiler. 1996. West Nile virus neuroinvasion and encephalitis induced by macrophage depletion in mice. Arch. Virol. 141:459-469.
6. Ben-Nathan, D., et al. 2003. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J. Infect. Dis. 188:5-12.
7. Ben-Nathan, D., et al. 2009. Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection. BMC Infect. Dis. 9:18.
8. Bindon, C. I., G. Hale, M. Bruggemann, and H. Waldmann. 1988. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J. Exp. Med. 168:127-142.
9. Blaney, J. E., Jr., J. M. Matro, B. R. Murphy, and S. S. Whitehead. 2005. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J. Virol. 79:5516-5528.
10. Boere, W. A., et al. 1985. Mechanisms of monoclonal antibody-mediated protection against virulent Semliki Forest virus. J. Virol. 54:546-551.
11. Bond, J. O., and W. M. Hammon. 1970. Epidemiologic studies of possible cross protection between dengue and St. Louis encephalitis arboviruses in Florida. Am. J. Epidemiol. 92:321-329.
12. Brien, J. D., J. L. Uhrlaub, A. Hirsch, C. A. Wiley, and J. Nikolich-Zugich. 2009. Key role of T cell defects in age-related vulnerability to West Nile virus. J. Exp. Med. 206:2735-2745.
13. Cherrier, M. V., et al. 2009. Structural basis for the preferential binding of immature flaviviruses by a fusion-loop specific antibody. EMBO 28:3269- 3276.
14. Chung, K. M., et al. 2006. Antibodies against West Nile virus non-structural (NS)-1 protein prevent lethal infection through Fc gamma receptor-dependent and independent mechanisms. J. Virol. 80:1340-1351.
15. Chung, K. M., B. S. Thompson, D. H. Fremont, and M. S. Diamond. 2007. Antibody recognition of cell surface-associated NS1 triggers Fc-γ receptormediated phagocytosis and clearance of West Nile virus-infected cells. J. Virol. 81:9551-9555.
16. Crill, W. D., H. R. Hughes, M. J. Delorey, and G. J. Chang. 2009. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One 4:e4991.
17. Diamond, M. S., and R. S. Klein. 2006. A genetic basis for human susceptibility to West Nile virus. Trends Microbiol. 14:287-289.
18. Diamond, M. S., B. Shrestha, A. Marri, D. Mahan, and M. Engle. 2003. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J. Virol. 77:2578-2586.
19. Diamond, M. S., et al. 2003. A critical role for induced IgM in the protection against West Nile Virus infection. J. Exp. Med. 198:1853-1862.
20. Ebel, G. D., J. Carricaburu, D. Young, K. A. Bernard, and L. D. Kramer. 2004. Genetic and phenotypic variation of West Nile virus in New York, 2002-2003. Am. J. Trop. Med. Hyg. 71:493-500.
21. Egan, C. E., W. Sukhumavasi, A. L. Bierly, and E. Y. Denkers. 2008. Understanding the multiple functions of Gr-1(+) cell subpopulations during microbial infection. Immunol. Res. 40:35-48.
22. Engle, M., and M. S. Diamond. 2003. Antibody prophylaxis and therapy against West Nile Virus infection in wild type and immunodeficient mice. J. Virol. 77:12941-12949.
23. Ey, P. L., S. J. Prowse, and C. R. Jenkin. 1979. Complement-fixing IgG1 constitutes a new subclass of mouse IgG. Nature 281:492-493.
24. Fuchs, A., et al. 2010. Direct complement restriction of flavivirus infection requires glycan recognition by mannose binding lectin. Cell Host Microbe 8:186-195.
25. Gentry, M. K., E. A. Henchal, J. M. McCown, W. E. Brandt, and J. M. Dalrymple. 1982. Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies. Am. J. Trop. Med. Hyg. 31:548-555.
26. Glass, W. G., et al. 2006. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. Med. 203:35-40.
27. Gould, E. A., A. Buckley, A. D. Barrett, and N. Cammack. 1986. Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J. Gen. Virol. 67:591-595.
28. Gubler, D. J. 2007. The continuing spread of West Nile virus in the western hemisphere. Clin. Infect. Dis. 45:1039-1046.
29. Guirakhoo, F., F. X. Heinz, C. W. Mandl, H. Holzmann, and C. Kunz. 1991. Fusion activity of flaviviruses: comparison of mature and immature (prMcontaining) tick-borne encephalitis virions. J. Gen. Virol. 72:1323-1329.
30. Halstead, S. B. 2003. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 60:421-467.
31. Hammon, W. M., W. D. Tigertt, G. E. Sather, T. O. Berge, and G. Meiklejohn. 1958. Epidemiologic studies of concurrent virgin epidemics of Japanese B encephalitis and of mumps on Guam, 1947-1948, with subsequent observations including dengue, through 1957. Am. J. Trop. Med. Hyg. 7:441- 467.
32. Hessell, A. J., et al. 2009. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15:951- 954.
33. Junjhon, J., et al. 2010. Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles. J. Virol. 84:8353-8358.
34. Kaufman, B. M., et al. 1989. Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 41:576-580.
35. Komar, N., and G. G. Clark. 2006. West Nile virus activity in Latin America and the Caribbean. Rev. Panam. Salud Publica 19:112-117.
36. Kuhn, R. J., et al. 2002. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108:717-725.
37. Lefrancois, L. 1984. Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo. J. Virol. 51:208-214.
38. Levine, B., et al. 1991. Antibody-mediated clearance of alphavirus infection from neurons. Science 254:856-860.
39. Li, L., et al. 2008. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 319:1830-1834.
40. Lim, J. K., et al. 2009. Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog. 5:e1000321.
41. Lim, J. K., et al. 2008. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J. Infect. Dis. 197:262-265.
42. Lindenbach, B. D., and C. M. Rice. 2001. Flaviviridae: the viruses and their replication, p. 991-1041. In D. M. Knipe and P. M. Howley (ed.), Fields virology, vol. 1. Lippincott Williams & Wilkins, Philadelphia, PA.
43. Mehlhop, E., and M. S. Diamond. 2006. Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J. Exp. Med. 203:1371-1381.
44. Mehlhop, E., A. Fuchs, M. Engle, and M. S. Diamond. 2009. Complement modulates pathogenesis and antibody-dependent neutralization of West Nile virus infection through a C5-independent mechanism. Virology 393:11-15.
45. Mehlhop, E., et al. 2009. Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe 6:381-391.
46. Mendoza, Q. P., J. Stanley, and D. E. Griffin. 1988. Monoclonal antibodies to the E1 and E2 glycoproteins of Sindbis virus: definition of epitopes and efficiency of protection from fatal encephalitis. J. Gen. Virol. 69:3015-3022.
47. Michaud, H. A., et al. 2010. A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy. PLoS Pathog. 6:e1000948.
48. Morrey, J. D., et al. 2006. Humanized monoclonal antibody against West Nile virus E protein administered after neuronal infection protects against lethal encephalitis in hamsters. J. Infect. Dis. 194:1300-1308.
49. Murphy, B. R., and S. S. Whitehead. 2011. Immune response to dengue virus and prospects for a vaccine. Annu. Rev. Immunol. 29:587-619.
50. Nakanaga, K., K. Yamanouchi, and K. Fujiwara. 1986. Protective effect of monoclonal antibodies on lethal mouse hepatitis virus infection in mice. J. Virol. 59:168-171.
51. Nelson, S., et al. 2008. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog. 4:e1000060.
52. Nimmerjahn, F., and J. V. Ravetch. 2006. Fcγ receptors: old friends and new family members. Immunity 24:19-28.
53. Oliphant, T., et al. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nature Med. 11:522-530.
54. Oliphant, T., et al. 2007. The induction of epitope-specific neutralizing antibodies against West Nile virus. J. Virol. 81:11828-11839.
55. Oliphant, T., et al. 2006. Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J. Virol. 80:12149-12159.
56. Petersen, L. R., and E. B. Hayes. 2008. West Nile virus in the Americas. Med. Clin. North Am. 92:1307-1322.
57. Pierson, T. C., and M. S. Diamond. 2008. Molecular mechanisms of antibody-mediated neutralization of flavivirus infection. Exp. Rev. Mol. Med. 10:e12.
58. Pierson, T. C., D. H. Fremont, R. J. Kuhn, and M. S. Diamond. 2008. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4:229-238.
59. Pierson, T. C., et al. 2007. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1:135-145.
60. Purtha, W. E., K. A. Chachu, H. W. Virgin, and M. S. Diamond. 2008. Early B-cell activation after West Nile virus infection requires alpha/beta interferon but not antigen receptor signaling. J. Virol. 82:10964-10974.
61. Putnak, J. R., et al. 2008. Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies. Am. J. Trop. Med. Hyg. 79:115-122.
62. Ravetch, J. V., and S. Bolland. 2001. IgG Fc receptors. Annu. Rev. Immunol. 19:275-290.
63. Rodriguez Mde, L., et al. 2010. Serologic surveillance for West Nile virus and other flaviviruses in febrile patients, encephalitic patients, and asymptomatic blood donors in northern Mexico. Vector Borne Zoonotic Dis. 10:151-157.
64. Sanchez, M. D., et al. 2005. Characterization of neutralizing antibodies to West Nile virus. Virology 336:70-82.
65. Schlesinger, J. J., and S. Chapman. 1995. Neutralizing F(ab')2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis. J. Gen. Virol. 76: 217-220.
66. Schmaljohn, A. L., E. D. Johnson, J. M. Dalrymple, and G. A. Cole. 1982. Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis. Nature 297:70-72.
67. Sejvar, J. J., et al. 2003. Neurologic manifestations and outcome of West Nile virus infection. JAMA 290:511-515.
68. Shrestha, B., M. A. Samuel, and M. S. Diamond. 2006. CD8+ T cells require perforin to clear West Nile virus from infected neurons. J. Virol. 80:119-129.
69. Stiasny, K., S. Kiermayr, H. Holzmann, and F. X. Heinz. 2006. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J. Virol. 80:9557-9568.
70. Sukupolvi-Petty, S., et al. 2010. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J. Virol. 84:9227- 9239.
71. Sultana, H., et al. 2009. Fusion loop peptide of the West Nile virus envelope protein is essential for pathogenesis and is recognized by a therapeutic cross-reactive human monoclonal antibody. J. Immunol. 183:650-660.
72. Tao, M. H., and S. L. Morrison. 1989. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J. Immunol. 143:2595- 2601.
73. Teixeira, H. C., and S. H. Kaufmann. 1994. Role of NK1.1 cells in experimental listeriosis. NK1 cells are early IFN-gamma producers but impair resistance to Listeria monocytogenes infection. J. Immunol. 152:1873-1882.
74. Tesh, R. B., et al. 2002. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. Emerg. Infect. Dis. 8:1392-1397.
75. Throsby, M., et al. 2006. Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J. Virol. 80:6982-6992.
76. Tyler, K. L., M. A. Mann, B. N. Fields, and H. W. Virgin, IV. 1993. Protective antireovirus monoclonal antibodies and their effects on viral pathogenesis. J. Virol. 67:3446-3453.
77. van Rooijen, N. 1994. Liposome mediated modulation of macrophage functions. Adv. Exp. Med. Biol. 355:69-74.
78. van Rooijen, N., and E. Hendrikx. 2010. Liposomes for specific depletion of macrophages from organs and tissues. Methods Mol. Biol. 605:189-203.
79. Van Rooijen, N., and A. Sanders. 1994. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J. Immunol. Methods 174:83-93.
80. Vogt, M. R., et al. 2009. Human monoclonal antibodies induced by natural infection against West Nile virus neutralize at a postattachment step. J. Virol. 83:6494-6507.
81. Wright, D. E., S. Colaco, C. Colaco, and P. G. Stevenson. 2009. Antibody limits in vivo murid herpesvirus-4 replication by IgG Fc receptor-dependent functions. J. Gen. Virol. 90:2592-2603.
82. Yu, I. M., et al. 2008. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 319:1834-1837.
83. Zhang, S., et al. 2009. The development of resistance to passive therapy by a potently neutralizing humanized West Nile virus monoclonal antibody. J. Infect. Dis. 200:202-205.
84. Zhang, Y., et al. 2003. Structures of immature flavivirus particles. EMBO J. 22:2604-2613.